Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 171

1.

Longitudinal analysis of cerebral aqueduct flow measures: multiple sclerosis flow changes driven by brain atrophy.

Jakimovski D, Zivadinov R, Weinstock-Guttman B, Bergsland N, Dwyer MG, Lagana MM.

Fluids Barriers CNS. 2020 Jan 31;17(1):9. doi: 10.1186/s12987-020-0172-3.

2.

A multimodal approach to assess the validity of atrophied T2-lesion volume as an MRI marker of disease progression in multiple sclerosis.

Tavazzi E, Bergsland N, Kuhle J, Jakimovski D, Ramanathan M, Maceski AM, Tomic D, Hagemeier J, Kropshofer H, Leppert D, Dwyer MG, Weinstock-Guttman B, Benedict RHB, Zivadinov R.

J Neurol. 2019 Nov 25. doi: 10.1007/s00415-019-09643-z. [Epub ahead of print]

PMID:
31768628
3.

Early signs of right ventricular systolic and diastolic dysfunction in acute severe respiratory failure: the importance of diastolic restrictive pattern.

Tavazzi G, Bergsland N, Alcada J, Price S.

Eur Heart J Acute Cardiovasc Care. 2019 Nov 25:2048872619883399. doi: 10.1177/2048872619883399. [Epub ahead of print]

PMID:
31762290
4.

White matter alterations in early Parkinson's disease: role of motor symptom lateralization.

Pelizzari L, Di Tella S, Laganà MM, Bergsland N, Rossetto F, Nemni R, Baglio F.

Neurol Sci. 2020 Feb;41(2):357-364. doi: 10.1007/s10072-019-04084-y. Epub 2019 Oct 24.

PMID:
31650438
5.

Targeting Iron Dyshomeostasis for Treatment of Neurodegenerative Disorders.

Bergsland N, Tavazzi E, Schweser F, Jakimovski D, Hagemeier J, Dwyer MG, Zivadinov R.

CNS Drugs. 2019 Nov;33(11):1073-1086. doi: 10.1007/s40263-019-00668-6.

PMID:
31556017
6.

Atrophied Brain T2 Lesion Volume at MRI Is Associated with Disability Progression and Conversion to Secondary Progressive Multiple Sclerosis.

Genovese AV, Hagemeier J, Bergsland N, Jakimovski D, Dwyer MG, Ramasamy DP, Lizarraga AA, Hojnacki D, Kolb C, Weinstock-Guttman B, Zivadinov R.

Radiology. 2019 Nov;293(2):424-433. doi: 10.1148/radiol.2019190306. Epub 2019 Sep 24.

PMID:
31549947
7.

Teriflunomide's effect on humoral response to Epstein-Barr virus and development of cortical gray matter pathology in multiple sclerosis.

Zivadinov R, Ramanathan M, Hagemeier J, Bergsland N, Ramasamy DP, Durfee J, Kolb C, Weinstock-Guttman B.

Mult Scler Relat Disord. 2019 Nov;36:101388. doi: 10.1016/j.msard.2019.101388. Epub 2019 Sep 9.

PMID:
31525628
8.

re: Reliability of 3D Texture Analysis: A Multicenter MRI Study of the Brain.

Bergsland N.

J Magn Reson Imaging. 2019 Sep 11. doi: 10.1002/jmri.26923. [Epub ahead of print] No abstract available.

PMID:
31507009
9.

Preserved network functional connectivity underlies cognitive reserve in multiple sclerosis.

Fuchs TA, Benedict RHB, Bartnik A, Choudhery S, Li X, Mallory M, Oship D, Yasin F, Ashton K, Jakimovski D, Bergsland N, Ramasamy DP, Weinstock-Guttman B, Zivadinov R, Dwyer MG.

Hum Brain Mapp. 2019 Dec 15;40(18):5231-5241. doi: 10.1002/hbm.24768. Epub 2019 Aug 24.

PMID:
31444887
10.

Serum neurofilament light chain levels associations with gray matter pathology: a 5-year longitudinal study.

Jakimovski D, Kuhle J, Ramanathan M, Barro C, Tomic D, Hagemeier J, Kropshofer H, Bergsland N, Leppert D, Dwyer MG, Michalak Z, Benedict RHB, Weinstock-Guttman B, Zivadinov R.

Ann Clin Transl Neurol. 2019 Sep;6(9):1757-1770. doi: 10.1002/acn3.50872. Epub 2019 Aug 22. Erratum in: Ann Clin Transl Neurol. 2019 Dec;6(12):2607.

11.

Plasma levels of protein C pathway proteins and brain magnetic resonance imaging volumes in multiple sclerosis.

Ziliotto N, Zivadinov R, Baroni M, Marchetti G, Jakimovski D, Bergsland N, Ramasamy DP, Weinstock-Guttman B, Straudi S, Manfredini F, Ramanathan M, Bernardi F.

Eur J Neurol. 2020 Feb;27(2):235-243. doi: 10.1111/ene.14058. Epub 2019 Sep 8.

PMID:
31408242
12.

Cholesterol and neurodegeneration: longitudinal changes in serum cholesterol biomarkers are associated with new lesions and gray matter atrophy in multiple sclerosis over 5 years of follow-up.

Murali N, Browne RW, Fellows Maxwell K, Bodziak ML, Jakimovski D, Hagemeier J, Bergsland N, Weinstock-Guttman B, Zivadinov R, Ramanathan M.

Eur J Neurol. 2020 Jan;27(1):188-e4. doi: 10.1111/ene.14055. Epub 2019 Aug 19.

PMID:
31369181
13.

Cumulative gadodiamide administration leads to brain gadolinium deposition in early MS.

Zivadinov R, Bergsland N, Hagemeier J, Ramasamy DP, Dwyer MG, Schweser F, Kolb C, Weinstock-Guttman B, Hojnacki D.

Neurology. 2019 Aug 6;93(6):e611-e623. doi: 10.1212/WNL.0000000000007892. Epub 2019 Jul 8.

PMID:
31285398
14.

Salient Central Lesion Volume: A Standardized Novel Fully Automated Proxy for Brain FLAIR Lesion Volume in Multiple Sclerosis.

Dwyer MG, Bergsland N, Ramasamy DP, Weinstock-Guttman B, Barnett MH, Wang C, Tomic D, Silva D, Zivadinov R.

J Neuroimaging. 2019 Sep;29(5):615-623. doi: 10.1111/jon.12650. Epub 2019 Jul 1.

PMID:
31259467
15.

Trait Conscientiousness predicts rate of brain atrophy in multiple sclerosis.

Fuchs TA, Benedict RH, Wilding G, Wojcik C, Jakimovski D, Bergsland N, Ramasamy DP, Weinstock-Guttman B, Zivadinov R, Dwyer MG.

Mult Scler. 2019 Jun 20:1352458519858605. doi: 10.1177/1352458519858605. [Epub ahead of print]

PMID:
31219390
16.

Combined Assessment of Diffusion Parameters and Cerebral Blood Flow Within Basal Ganglia in Early Parkinson's Disease.

Pelizzari L, Laganà MM, Di Tella S, Rossetto F, Bergsland N, Nemni R, Clerici M, Baglio F.

Front Aging Neurosci. 2019 Jun 4;11:134. doi: 10.3389/fnagi.2019.00134. eCollection 2019.

17.

Ventral posterior substantia nigra iron increases over 3 years in Parkinson's disease.

Bergsland N, Zivadinov R, Schweser F, Hagemeier J, Lichter D, Guttuso T Jr.

Mov Disord. 2019 Jul;34(7):1006-1013. doi: 10.1002/mds.27730. Epub 2019 Jun 10.

PMID:
31180615
18.

Corrigendum to "MR microneurography and quantitative T2 and DP measurements of the distal tibial nerve in CIDP" [Journal of the Neurological Sciences Volume 400, 15 May 2019, Pages 15-20].

Felisaz PF, Poli A, Vitale R, Vitale G, Asteggiano C, Bergsland N, Callegari I, Vegezzi E, Piccolo L, Cortese A, Pichiecchio A, Bastianello S.

J Neurol Sci. 2019 Aug 15;403:169. doi: 10.1016/j.jns.2019.05.035. Epub 2019 Jun 6. No abstract available.

PMID:
31178081
19.

Cerebrovascular reactivity and its correlation with age in patients with multiple sclerosis.

Pelizzari L, Laganà MM, Baglio F, Bergsland N, Cecconi P, Viotti S, Pugnetti L, Nemni R, Baselli G, Clerici M, Mendozzi L.

Brain Imaging Behav. 2019 Jun 7. doi: 10.1007/s11682-019-00132-5. [Epub ahead of print]

PMID:
31175576
20.

Aging and Brain Atrophy in Multiple Sclerosis.

Ghione E, Bergsland N, Dwyer MG, Hagemeier J, Jakimovski D, Paunkoski I, Ramasamy DP, Carl E, Hojnacki D, Kolb C, Weinstock-Guttman B, Zivadinov R.

J Neuroimaging. 2019 Jul;29(4):527-535. doi: 10.1111/jon.12625. Epub 2019 May 10.

PMID:
31074192
21.

Cerebral blood flow and cerebrovascular reactivity correlate with severity of motor symptoms in Parkinson's disease.

Pelizzari L, Laganà MM, Rossetto F, Bergsland N, Galli M, Baselli G, Clerici M, Nemni R, Baglio F.

Ther Adv Neurol Disord. 2019 Mar 21;12:1756286419838354. doi: 10.1177/1756286419838354. eCollection 2019.

22.

MR microneurography and quantitative T2 and DP measurements of the distal tibial nerve in CIDP.

Felisaz PF, Poli A, Vitale R, Vitale G, Asteggiano C, Bergsland N, Callegari I, Vegezzi E, Piccolo L, Cortese A, Pichiecchio A, Bastianello S.

J Neurol Sci. 2019 May 15;400:15-20. doi: 10.1016/j.jns.2019.03.001. Epub 2019 Mar 11. Erratum in: J Neurol Sci. 2019 Aug 15;403:169.

PMID:
30878635
23.

Leptomeningeal Contrast Enhancement Is Related to Focal Cortical Thinning in Relapsing-Remitting Multiple Sclerosis: A Cross-Sectional MRI Study.

Bergsland N, Ramasamy D, Tavazzi E, Hojnacki D, Weinstock-Guttman B, Zivadinov R.

AJNR Am J Neuroradiol. 2019 Apr;40(4):620-625. doi: 10.3174/ajnr.A6011. Epub 2019 Mar 14.

24.

Effect of Teriflunomide and Dimethyl Fumarate on Cortical Atrophy and Leptomeningeal Inflammation in Multiple Sclerosis: A Retrospective, Observational, Case-Control Pilot Study.

Zivadinov R, Bergsland N, Carl E, Ramasamy DP, Hagemeier J, Dwyer MG, Lizarraga AA, Kolb C, Hojnacki D, Weinstock-Guttman B.

J Clin Med. 2019 Mar 12;8(3). pii: E344. doi: 10.3390/jcm8030344.

25.

A Serial 10-Year Follow-Up Study of Atrophied Brain Lesion Volume and Disability Progression in Patients with Relapsing-Remitting MS.

Zivadinov R, Horakova D, Bergsland N, Hagemeier J, Ramasamy DP, Uher T, Vaneckova M, Havrdova E, Dwyer MG.

AJNR Am J Neuroradiol. 2019 Mar;40(3):446-452. doi: 10.3174/ajnr.A5987. Epub 2019 Feb 28.

PMID:
30819766
26.

Dietary and lifestyle factors in multiple sclerosis progression: results from a 5-year longitudinal MRI study.

Jakimovski D, Weinstock-Guttman B, Gandhi S, Guan Y, Hagemeier J, Ramasamy DP, Fuchs TA, Browne RW, Bergsland N, Dwyer MG, Ramanathan M, Zivadinov R.

J Neurol. 2019 Apr;266(4):866-875. doi: 10.1007/s00415-019-09208-0. Epub 2019 Feb 13.

PMID:
30758665
27.

Higher EBV response is associated with more severe gray matter and lesion pathology in relapsing multiple sclerosis patients: A case-controlled magnetization transfer ratio study.

Jakimovski D, Ramanathan M, Weinstock-Guttman B, Bergsland N, Ramasamay DP, Carl E, Dwyer MG, Zivadinov R.

Mult Scler. 2019 Feb 13:1352458519828667. doi: 10.1177/1352458519828667. [Epub ahead of print]

PMID:
30755085
28.

Comparative effectiveness of teriflunomide and dimethyl fumarate in patients with relapsing forms of MS in the retrospective real-world Teri-RADAR study.

Zivadinov R, Kresa-Reahl K, Weinstock-Guttman B, Edwards K, Burudpakdee C, Bergsland N, Dwyer MG, Khatri B, Thangavelu K, Chavin J, Mandel M, Cohan S.

J Comp Eff Res. 2019 Apr;8(5):305-316. doi: 10.2217/cer-2018-0135. Epub 2019 Feb 13.

29.

Lower total cerebral arterial flow contributes to cognitive performance in multiple sclerosis patients.

Jakimovski D, Benedict RH, Marr K, Gandhi S, Bergsland N, Weinstock-Guttman B, Zivadinov R.

Mult Scler. 2020 Feb;26(2):201-209. doi: 10.1177/1352458518819608. Epub 2019 Jan 9.

PMID:
30625030
30.

Atrophied brain lesion volume, a magnetic resonance imaging biomarker for monitoring neurodegenerative changes in multiple sclerosis.

Zivadinov R, Bergsland N, Dwyer MG.

Quant Imaging Med Surg. 2018 Nov;8(10):979-983. doi: 10.21037/qims.2018.11.01. No abstract available.

31.

Are Plasma Levels of Vascular Adhesion Protein-1 Associated Both with Cerebral Microbleeds in Multiple Sclerosis and Intracerebral Haemorrhages in Stroke?

Ziliotto N, Zivadinov R, Jakimovski D, Bergsland N, Ramasamy DP, Weinstock-Guttman B, Ramanathan M, Marchetti G, Bernardi F.

Thromb Haemost. 2019 Jan;119(1):175-178. doi: 10.1055/s-0038-1676346. Epub 2018 Dec 31.

PMID:
30597511
32.

Are Cerebral Perfusion and Atrophy Linked in Multiple Sclerosis? Evidence for a Multifactorial Approach to Assess Neurodegeneration.

Laganá MM, Mendozzi L, Pelizzari L, Bergsland NP, Pugnetti L, Cecconi P, Baselli G, Clerici M, Nemni R, Baglio F.

Curr Neurovasc Res. 2018;15(4):282-291. doi: 10.2174/1567202616666181123164235.

PMID:
30468125
33.

Brain Atrophy Is Associated with Disability Progression in Patients with MS followed in a Clinical Routine.

Ghione E, Bergsland N, Dwyer MG, Hagemeier J, Jakimovski D, Paunkoski I, Ramasamy DP, Silva D, Carl E, Hojnacki D, Kolb C, Weinstock-Guttman B, Zivadinov R.

AJNR Am J Neuroradiol. 2018 Dec;39(12):2237-2242. doi: 10.3174/ajnr.A5876. Epub 2018 Nov 22.

34.

Assessment of mesoscopic properties of deep gray matter iron through a model-based simultaneous analysis of magnetic susceptibility and R2* - A pilot study in patients with multiple sclerosis and normal controls.

Taege Y, Hagemeier J, Bergsland N, Dwyer MG, Weinstock-Guttman B, Zivadinov R, Schweser F.

Neuroimage. 2019 Feb 1;186:308-320. doi: 10.1016/j.neuroimage.2018.11.011. Epub 2018 Nov 14.

35.

Plasma levels of soluble NCAM in multiple sclerosis.

Ziliotto N, Zivadinov R, Jakimovski D, Baroni M, Tisato V, Secchiero P, Bergsland N, Ramasamy DP, Weinstock-Guttman B, Bernardi F, Ramanathan M, Marchetti G.

J Neurol Sci. 2019 Jan 15;396:36-41. doi: 10.1016/j.jns.2018.10.023. Epub 2018 Oct 28.

PMID:
30412901
36.

Impact of fingolimod on clinical and magnetic resonance imaging outcomes in routine clinical practice: A retrospective analysis of the multiple sclerosis, clinical and MRI outcomes in the USA (MS-MRIUS) study.

Zivadinov R, Medin J, Khan N, Korn JR, Chitnis T, Naismith RT, Alvarez E, Dwyer MG, Bergsland N, Carl E, Silva D, Weinstock-Guttman B; MS-MRIUS Study Group.

Mult Scler Relat Disord. 2019 Jan;27:65-73. doi: 10.1016/j.msard.2018.09.037. Epub 2018 Oct 3.

PMID:
30342416
37.

Walking disability measures in multiple sclerosis patients: Correlations with MRI-derived global and microstructural damage.

Jakimovski D, Weinstock-Guttman B, Hagemeier J, Vaughn CB, Kavak KS, Gandhi S, Bennett SE, Fuchs TA, Bergsland N, Dwyer MG, Benedict RHB, Zivadinov R.

J Neurol Sci. 2018 Oct 15;393:128-134. doi: 10.1016/j.jns.2018.08.020. Epub 2018 Aug 23.

PMID:
30165291
38.

Abnormal venous postural control: multiple sclerosis-specific change related to gray matter pathology or age-related neurodegenerative phenomena?

Jakimovski D, Topolski M, Kimura K, Marr K, Gandhi S, Ramasamy DP, Bergsland N, Hagemeier J, Weinstock-Guttman B, Zivadinov R.

Clin Auton Res. 2019 Jun;29(3):329-338. doi: 10.1007/s10286-018-0555-6. Epub 2018 Aug 17.

PMID:
30120624
39.

Hypertension and heart disease are associated with development of brain atrophy in multiple sclerosis: a 5-year longitudinal study.

Jakimovski D, Gandhi S, Paunkoski I, Bergsland N, Hagemeier J, Ramasamy DP, Hojnacki D, Kolb C, Benedict RHB, Weinstock-Guttman B, Zivadinov R.

Eur J Neurol. 2019 Jan;26(1):87-e8. doi: 10.1111/ene.13769. Epub 2018 Sep 3.

PMID:
30103277
40.

Multimodal Imaging of Retired Professional Contact Sport Athletes Does Not Provide Evidence of Structural and Functional Brain Damage.

Zivadinov R, Polak P, Schweser F, Bergsland N, Hagemeier J, Dwyer MG, Ramasamy DP, Baker JG, Leddy JJ, Willer BS.

J Head Trauma Rehabil. 2018 Sep/Oct;33(5):E24-E32. doi: 10.1097/HTR.0000000000000422.

41.

Five-Year Longitudinal Study of Neck Vessel Cross-Sectional Area in Multiple Sclerosis.

Pelizzari L, Jakimovski D, Laganà MM, Bergsland N, Hagemeier J, Baselli G, Weinstock-Guttman B, Zivadinov R.

AJNR Am J Neuroradiol. 2018 Sep;39(9):1703-1709. doi: 10.3174/ajnr.A5738. Epub 2018 Jul 26.

42.

Increased CCL18 plasma levels are associated with neurodegenerative MRI outcomes in multiple sclerosis patients.

Ziliotto N, Bernardi F, Jakimovski D, Baroni M, Bergsland N, Ramasamy DP, Weinstock-Guttman B, Zamboni P, Marchetti G, Zivadinov R, Ramanathan M.

Mult Scler Relat Disord. 2018 Oct;25:37-42. doi: 10.1016/j.msard.2018.07.009. Epub 2018 Jul 7.

PMID:
30031282
43.

Brain Iron at Quantitative MRI Is Associated with Disability in Multiple Sclerosis.

Zivadinov R, Tavazzi E, Bergsland N, Hagemeier J, Lin F, Dwyer MG, Carl E, Kolb C, Hojnacki D, Ramasamy D, Durfee J, Weinstock-Guttman B, Schweser F.

Radiology. 2018 Nov;289(2):487-496. doi: 10.1148/radiol.2018180136. Epub 2018 Jul 17.

44.

Altered nuclei-specific thalamic functional connectivity patterns in multiple sclerosis and their associations with fatigue and cognition.

Lin F, Zivadinov R, Hagemeier J, Weinstock-Guttman B, Vaughn C, Gandhi S, Jakimovski D, Hulst HE, Benedict RH, Bergsland N, Fuchs T, Dwyer MG.

Mult Scler. 2019 Aug;25(9):1243-1254. doi: 10.1177/1352458518788218. Epub 2018 Jul 13.

PMID:
30004291
45.

Impact of Focal White Matter Damage on Localized Subcortical Gray Matter Atrophy in Multiple Sclerosis: A 5-Year Study.

Fuchs TA, Carolus K, Benedict RHB, Bergsland N, Ramasamy D, Jakimovski D, Weinstock-Guttman B, Kuceyeski A, Zivadinov R, Dwyer MG.

AJNR Am J Neuroradiol. 2018 Aug;39(8):1480-1486. doi: 10.3174/ajnr.A5720. Epub 2018 Jul 5.

46.

Thalamic white matter in multiple sclerosis: A combined diffusion-tensor imaging and quantitative susceptibility mapping study.

Bergsland N, Schweser F, Dwyer MG, Weinstock-Guttman B, Benedict RHB, Zivadinov R.

Hum Brain Mapp. 2018 Oct;39(10):4007-4017. doi: 10.1002/hbm.24227. Epub 2018 Jun 19.

47.

Atrophied Brain Lesion Volume: A New Imaging Biomarker in Multiple Sclerosis.

Dwyer MG, Bergsland N, Ramasamy DP, Jakimovski D, Weinstock-Guttman B, Zivadinov R.

J Neuroimaging. 2018 Sep;28(5):490-495. doi: 10.1111/jon.12527. Epub 2018 Jun 1.

PMID:
29856910
48.

Hemostasis biomarkers in multiple sclerosis.

Ziliotto N, Bernardi F, Jakimovski D, Baroni M, Marchetti G, Bergsland N, Ramasamy DP, Weinstock-Guttman B, Schweser F, Zamboni P, Ramanathan M, Zivadinov R.

Eur J Neurol. 2018 Sep;25(9):1169-1176. doi: 10.1111/ene.13681. Epub 2018 Jun 26.

PMID:
29758118
49.

Fingolimod's Impact on MRI Brain Volume Measures in Multiple Sclerosis: Results from MS-MRIUS.

Zivadinov R, Medin J, Khan N, Korn JR, Bergsland N, Dwyer MG, Chitnis T, Naismith RT, Alvarez E, Kinkel P, Cohan S, Hunter SF, Silva D, Weinstock-Guttman B; MS-MRIUS investigators.

J Neuroimaging. 2018 Jul;28(4):399-405. doi: 10.1111/jon.12518. Epub 2018 May 11.

PMID:
29749661
50.

Effects of motor rehabilitation on mobility and brain plasticity in multiple sclerosis: a structural and functional MRI study.

Tavazzi E, Bergsland N, Cattaneo D, Gervasoni E, Laganà MM, Dipasquale O, Grosso C, Saibene FL, Baglio F, Rovaris M.

J Neurol. 2018 Jun;265(6):1393-1401. doi: 10.1007/s00415-018-8859-y. Epub 2018 Apr 7.

PMID:
29627940

Supplemental Content

Loading ...
Support Center